Free Trial

Integra LifeSciences Q2 2023 Earnings Report

Integra LifeSciences logo
$21.80 +0.09 (+0.41%)
(As of 12/20/2024 05:31 PM ET)

Integra LifeSciences EPS Results

Actual EPS
$0.71
Consensus EPS
$0.57
Beat/Miss
Beat by +$0.14
One Year Ago EPS
$0.82

Integra LifeSciences Revenue Results

Actual Revenue
$381.30 million
Expected Revenue
$388.79 million
Beat/Miss
Missed by -$7.49 million
YoY Revenue Growth
-4.10%

Integra LifeSciences Announcement Details

Quarter
Q2 2023
Time
Before Market Opens

Conference Call Resources

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

Integra LifeSciences Earnings Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Integra Lifesciences Implements New Severance Program for Executives
See More Integra LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integra LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integra LifeSciences and other key companies, straight to your email.

About Integra LifeSciences

Integra LifeSciences (NASDAQ:IART) manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

View Integra LifeSciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings